Extendicare Inc. (TSE:EXE – Free Report) – Research analysts at Leede Financial upped their FY2024 earnings per share (EPS) estimates for shares of Extendicare in a report issued on Wednesday, November 13th. Leede Financial analyst D. Loe now expects that the company will post earnings of $1.03 per share for the year, up from their previous estimate of $0.89. The consensus estimate for Extendicare’s current full-year earnings is $0.61 per share. Leede Financial also issued estimates for Extendicare’s FY2027 earnings at $1.49 EPS.
EXE has been the topic of a number of other reports. Royal Bank of Canada raised their price objective on Extendicare from C$8.50 to C$9.50 in a research note on Monday, August 19th. TD Securities increased their price objective on shares of Extendicare from C$9.50 to C$10.50 and gave the company a “hold” rating in a research note on Thursday.
Extendicare Stock Up 1.3 %
Extendicare stock opened at C$10.14 on Friday. Extendicare has a 1-year low of C$6.41 and a 1-year high of C$10.43. The firm’s fifty day simple moving average is C$9.27 and its 200-day simple moving average is C$8.15. The company has a market capitalization of C$846.39 million, a P/E ratio of 14.91 and a beta of 1.26. The company has a current ratio of 0.60, a quick ratio of 0.98 and a debt-to-equity ratio of 305.80.
Extendicare Dividend Announcement
The firm also recently declared a monthly dividend, which was paid on Friday, November 15th. Investors of record on Thursday, October 31st were given a dividend of $0.04 per share. The ex-dividend date of this dividend was Thursday, October 31st. This represents a $0.48 dividend on an annualized basis and a yield of 4.73%. Extendicare’s dividend payout ratio (DPR) is presently 70.59%.
Extendicare Company Profile
Extendicare Inc, through its subsidiaries, provides care and services for seniors in Canada. The company offers long term care (LTC) services; and home health care services, such as nursing care, occupational, physical and speech therapy, and assistance with daily activities, as well as management, consulting, and other services to third parties.
Recommended Stories
- Five stocks we like better than Extendicare
- What Investors Need to Know About Upcoming IPOs
- ORIC: Working with Two Pharma Giants, Analysts See +100% Upside
- Investing In Preferred Stock vs. Common Stock
- Freeport-McMoRan, Copper Demand Short-Term Pain, Long-Term Gain
- The 3 Best Retail Stocks to Shop for in August
- Time to Load Up on Home Builders?
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.